PHARMALUNDENSIS AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.36 SEK | +1.69% |
|
-.--% | -20.70% |
| May. 16 | PharmaLundensis AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 15 | PharmaLundensis AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 42.55 | 35.81 | 22.93 | 29.15 | 24.06 | 16.43 |
| Enterprise Value (EV) 1 | 40.33 | 36.46 | 25.78 | 32.4 | 28.35 | 19.08 |
| P/E ratio | -8.16 x | -6.49 x | -7.18 x | -11.2 x | -7.32 x | -4.35 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -7.94 x | -7.07 x | -9.87 x | -16.6 x | -10.8 x | -6.67 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 5.79 x | 5.83 x | 7.78 x | 9.11 x | 13.7 x | 6.06 x |
| Nbr of stocks (in thousands) | 21,275 | 23,713 | 24,661 | 27,758 | 29,779 | 36,179 |
| Reference price 2 | 2.000 | 1.510 | 0.9300 | 1.050 | 0.8080 | 0.4540 |
| Announcement Date | 5/21/19 | 6/8/20 | 5/25/21 | 6/9/22 | 5/8/23 | 5/5/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -5.077 | -5.16 | -2.612 | -1.951 | -2.616 | -2.859 |
| EBIT 1 | -5.486 | -5.568 | -2.86 | -2.198 | -2.826 | -3.887 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -5.487 | -5.736 | -3.195 | -2.609 | -3.286 | -4.4 |
| Net income 1 | -5.487 | -5.736 | -3.195 | -2.609 | -3.286 | -4.4 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.2450 | -0.2326 | -0.1296 | -0.0940 | -0.1103 | -0.1043 |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 5/21/19 | 6/8/20 | 5/25/21 | 6/9/22 | 5/8/23 | 5/5/24 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 0.65 | 2.84 | 3.25 | 4.29 | 2.65 |
| Net Cash position 1 | 2.22 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -0.1269 x | -1.088 x | -1.667 x | -1.64 x | -0.9278 x |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -71.3% | -82.7% | -70.3% | -84.9% | -133% | -179% |
| ROA (Net income/ Total Assets) | -36.9% | -36% | -20.2% | -17.2% | -20.7% | -24.6% |
| Assets 1 | 14.86 | 15.92 | 15.84 | 15.17 | 15.88 | 17.86 |
| Book Value Per Share 2 | 0.3500 | 0.2600 | 0.1200 | 0.1200 | 0.0600 | 0.0700 |
| Cash Flow per Share 2 | 0.1000 | 0.0600 | 0.0400 | 0.0300 | 0.0100 | 0.0600 |
| Capex | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 5/21/19 | 6/8/20 | 5/25/21 | 6/9/22 | 5/8/23 | 5/5/24 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- PHAL Stock
- Financials PharmaLundensis AB
